Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

NCT01480154 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

62

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Solid Neoplasm
Stage III Cutaneous Melanoma AJCC v7
Stage III Prostate Cancer AJCC v7
Stage III Renal Cell Cancer AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
Stage IV Prostate Cancer AJCC v7
Stage IV Renal Cell Cancer AJCC v7

Interventions

DRUG: Akt Inhibitor MK2206
DRUG: Hydroxychloroquine

Sponsor

National Cancer Institute (NCI)